Investor Relations

Eidos is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need caused by transthyretin (TTR) amyloidosis (ATTR). The company’s investigational product candidate, acoramidis (AG10), is an orally-administered small molecule designed to stabilize TTR and prevent the formation of disease-causing amyloid, a therapeutic approach supported by genetic evidence as well as previous clinical trials. The development of acoramidis (AG10) is led by a proven management team who are responsible for developing over 30 molecules through IND applications and more than 10 marketed drugs. Together with patients and physicians, Eidos aims to bring a safe and effective treatment for ATTR to market as quickly as possible.

2019 Annual Report
Proxy Statement 

3 mo.
6 mo.
1 yr.

Data Provided by Refinitiv. Minimum 15 minutes delayed.